Acadia Pharmaceuticals Inc (NASDAQ:ACAD) Shorts Reduced By 2.01%

During 2018 Q2 the big money sentiment increased to 1.22. That’s change of 0.33, from 2018Q1’s 0.89. 31 investors sold all, 43 reduced holdings as ACADIA Pharmaceuticals Inc. ratio improved. 55 grew positions while 35 funds acquired positions. Funds hold 114.30 million shares thus 4.25% less from 2018Q1’s 119.37 million shares.
Credit Agricole S A stated it has 0% of its capital in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Baker Bros Advisors L P owns 27.23M shs or 3.12% of their US capital. Cubist Systematic Strategies Limited Co reported 29,655 shs. Schwab Charles Invest Management reported 0.01% of its capital in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Pub Employees Retirement Association Of Colorado has 18,333 shs. State Board Of Administration Of Florida Retirement Sys has 57,397 shs. Creative Planning holds 0.01% or 84,607 shs. Moneta Grp Inv Advisors Ltd owns 13 shs or 0% of their US capital. Bancorp Of Ny Mellon owns 440,808 shs. Vanguard Gp accumulated 8.67M shs. Utd Serv Automobile Association has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Tower Rech Cap (Trc) has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Northern Tru Corp holds 0% of its capital in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 1.27 million shs. Raymond James Financial Services stated it has 39,372 shs. Manufacturers Life Ins The accumulated 74,814 shs or 0% of the stock.

ACADIA Pharmaceuticals Inc. had 0 insider sales and 1 insider buy since September 20, 2018. This’s net activity of $22.65 million.

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) registered a decrease of 2.01% in short interest. It was announced in December by FINRA the 15.85 million short interest on ACAD. That’s 2.01% down from 16.17 million shares. Acadia Pharmaceuticals Inc (NASDAQ:ACAD) has 1.71M shares average volume. It’ll cost 9 days for ACAD to recover its former position. Acadia Pharmaceuticals Inc’s short interest float is 16.22%.

The stock decreased 3.70% or $0.7 during the last trading session, reaching $18.21.Currently ACADIA Pharmaceuticals Inc. is downtrending after 62.95% change in last December 8, 2017. ACAD has also 1.98 million shares volume. ACAD underperformed by 78.57% the S&P500.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.The firm is worth $2.62 billion. The firm offers NUPLAZID for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.Currently it has negative earnings. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

In total 7 analysts cover ACADIA Pharmaceuticals (NASDAQ:ACAD). “Buy” rating has 4, “Sell” are 0, while 3 are “Hold”. 57% are bullish. 10 are the (NASDAQ:ACAD)’s analyst reports since August 6, 2018 according to StockzIntelligence Inc. On Monday, August 6 the company was downgraded by PiperJaffray. In Thursday, August 9 report JMP Securities maintained it with “Market Outperform” rating and $27 target. On Thursday, November 1 the stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Overweight” rating given by Cantor Fitzgerald. On Wednesday, October 10 Bank of America maintained the shares of ACAD in report with “Buy” rating. On Tuesday, October 16 the firm earned “Overweight” rating by Cantor Fitzgerald. On Friday, September 21 the firm has “Overweight” rating by PiperJaffray given.

For more ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news posted recently go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Acadia Pharma files for shelf stock offering; shares down 7% after hours – Seeking Alpha” posted on November 26, 2018, “ACADIA Pharmaceuticals prices equity offering – Seeking Alpha” on November 28, 2018, “Noteworthy ETF Outflows: XBI, ACAD, IONS, ARRY – Nasdaq” with a publish date: November 16, 2018, “Wall Street Sees Another Round of Gains Amid Data; Q3 GDP Growth Stays at 3.5% – Nasdaq” and the last “40 Biggest Movers From Yesterday – Benzinga” with publication date: November 29, 2018.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.